1-(2-fluoro-5-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 1-(2-fluoro-5-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid
• 英文别名: 1-(2-Fluoro-5-propan-2-yloxybenzoyl)-6,7-dimethoxyisoquinoline-4-carboxylic acid
• 化学式: C₂₂H₂₀FNO₆
• 分子量: 413.402
• InChiKey: PZJIETQEHNYXCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  95
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1-(2-fluoro-5-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid 以 二甲基亚砜 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Discovery of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors

  摘要：

  Through high throughput screening and subsequent hit identification and optimization, we synthesized a series of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as the first reported potent and reversible GFAT inhibitors. SAR studies of this class of compounds indicated significant impact on GFAT inhibition potency by substitutions on the A-ring and C-ring. The ketone group was found to be necessary for high potency. Compound 28 (RO0509347) demonstrated potent GFAT inhibition (IC(50) = 1 mu M) with a desirable pharmacokinetic profile in rats, and showed significant efficacy in reducing the glucose excursion in an OGTT test in ob/ob mice. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.009
• 作为产物：
  描述：

  3,4-二甲氧基苯乙腈 在 palladium 10% on activated carbon 盐酸 、 sodium hydroxide 、 selenium(IV) oxide 、 乙醇 、 五氯化磷 、 水 、 氢气 、 sodium 、 1-羟基苯并三唑 、 sulfur 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 甲苯 为溶剂， 20.0~165.0 ℃ 、379.22 kPa 条件下， 反应 6.5h， 生成 1-(2-fluoro-5-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid
  参考文献：
  名称：

  [EN] ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS
  [FR] INHIBITEURS DE LA GFAT

  摘要：

  公开号：

  WO2004101528A3

文献信息

• Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors
  申请人：——

  公开号：US20040259910A1

  公开（公告）日：2004-12-23

  Compounds of formula I are provided 1 as well as pharmaceutically acceptable salts and esters thereof, wherein the substituents are as disclosed in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.

  提供了化学式I的化合物，以及其药学上可接受的盐和酯，其中取代基如规范中所披露。这些化合物可用于治疗2型糖尿病。
• [EN] ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS<br/>[FR] INHIBITEURS DE LA GFAT
  申请人：HOFFMANN LA ROCHE

  公开号：WO2004101528A3

  公开（公告）日：2005-01-06
• ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1631551A2

  公开（公告）日：2006-03-08
• US7067529B2
  申请人：——

  公开号：US7067529B2

  公开（公告）日：2006-06-27
• Discovery of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors
  作者：Yimin Qian、Mushtaq Ahmad、Shaoqing Chen、Paul Gillespie、Nam Le、Frank Mennona、Steven Mischke、Sung-Sau So、Hong Wang、Charles Burghardt、Shahid Tannu、Karin Conde-Knape、Jarema Kochan、David Bolin

  DOI：10.1016/j.bmcl.2011.09.009

  日期：2011.11

  Through high throughput screening and subsequent hit identification and optimization, we synthesized a series of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as the first reported potent and reversible GFAT inhibitors. SAR studies of this class of compounds indicated significant impact on GFAT inhibition potency by substitutions on the A-ring and C-ring. The ketone group was found to be necessary for high potency. Compound 28 (RO0509347) demonstrated potent GFAT inhibition (IC(50) = 1 mu M) with a desirable pharmacokinetic profile in rats, and showed significant efficacy in reducing the glucose excursion in an OGTT test in ob/ob mice. (C) 2011 Elsevier Ltd. All rights reserved.